2 hrs ago
Biotech Bust: 5 Drivers
What the heck happened to the biotechnology sector on Thursday ? It's continuing on Friday, with Gilead Sciences and iShares Nasdaq Biotechnology Index ETF down by 2% and 1.3%, respectively.
Trending on the Topix Network
10 hrs ago
Stocks with implied volatility movement; Gild Celg
Gilead weakness a buying opportunity, says Stifel Stifel sees the weakness in Gilead which was caused by Merck's announcement of a competitive drug, as a buying opportunity.
Thu Mar 06, 2014
Alnylam closes $175M purchase of Merck subsidiary
Alnylam Pharmaceuticals has closed its $175 million acquisition of Sirna Therapeutics Inc., a subsidiary of Merck & Co., it said Thursday.
View Press Release
Move reinforces business strategy to reach a minimum of 3% total share per key market and at least 3 leading brands in investment markets )--Merck's Consumer Health division has significantly increased in size following its incorporation of NeurobionA , a leading global brand in the vitamin B segment, and FloratilA , a leading brand in Brazil in ... (more)
Wed Mar 05, 2014
Merck's Investigational HIV Therapy, Doravirine (MK-1439),...
Merck , known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company's investigational next-generation, non-nucleoside reverse transcriptase inhibitor , at the 21st Conference on Retroviruses and Opportunistic Infections .
Merck & Co., Inc.'s Dust Mite Allergy Drug Reduces Symptoms In Phase 2b Study
Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet WHITEHOUSE STATION, N.J.-- -- Merck , known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual ... (more)
Tue Mar 04, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
Kindred's dedicatio... )--Getty Realty Corp. announced its financial results for the quarter and year ended December 31, 2013.
Collaborating online for the next breakthrough in life sciences
Sales and traffic to online retailers by category and merchant type, data on Amazon and other leading e-retailers, comparisons of leading web retailers, site performance data, more.
Mon Mar 03, 2014
GuruFocus Names Five Dividend Growers
During the past week, GuruFocus recognized five companies as dividend growers. In order to be qualified for this list, the company had to: The following five companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.
Portola Pharmaceuticals Inc - 10-K - Management's Discussion and...
You should read the following discussion and analysis of our financial condition and results of operations together with the section of this report entitled "Selected financial data" and our financial statements and related notes included elsewhere in this report.
Sat Mar 01, 2014
The Motley Fool
The 4 Surprising Stocks Leading the Dow Jones Industrials So Far in 2014
After five years of gains in one of the most powerful bull markets in recent memory, the Dow Jones Industrials have gotten off to a slow start in 2014.
Fri Feb 28, 2014
MERCK & CO. INC. FILES (8-K) Disclosing Amendments to Articles of...
MERCK & CO. INC. FILES Disclosing Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits amended Article I, Section 2 of the By-Laws of the Company to provide that special meetings of shareholders may be called by shareholders owning at least fifteen percent of the combined voting power of the then ... (more)
Overvaluing Liquidity: Invest For The Future, Not For Today
If you talk to individual investors about which stocks they own, you will undoubtedly hear a recitation of the same stocks that dominate the financial media on a daily basis.
Pensions & Investments
Merck to inject $250 million into pension funds this year
Merck & Co., Whitehouse Station, N.J., plans to contribute about $250 million to its defined benefit pension funds worldwide in 2014, according to its 10-K filed Thursday with the Securities and Exchange Commission.
CHMP Issues Positive Opinion for Tablet Formulation of Mercka s NOXAFIL
The CHMP positive opinion will be reviewed by the European Commission, which if approved, grants a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway.
Thu Feb 27, 2014
The Vaccine Prevnar 13 And Its Competitor: Pfizer Vs. Merck
In February Pfizer announced that its vaccine Prevnar 13 demonstrated efficacy in a trial of adults 65 years of age and older.
Wed Feb 26, 2014
NYSE Active Stock Watch List: Merck & Co. Inc. (NYSE:MRK) and...
Equity Profile Report expands its NYSE Active Stock Weekly Watch List adding Merck & Co.
Tue Feb 25, 2014
Stuart Weisbrod's Iguana Healthcare Management Is Fond of These Stocks
Management , a financial investment advisory firm, has an estimated $113 million of assets under management.
Drug Roundup - February 25, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.
Wall St. Cheat Sheet
Merck Abandons Once-Promising Experimental Cancer Drug to Ariad
Merck & Co. Inc. has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc. Merck informed Ariad last week that it was terminating its license agreement and handing back the drug to Ariad, FierceBiotech reports.